Can tiny zinc particles stop a deadly hospital superbug?
NCT ID NCT06628076
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study investigates whether zinc oxide nanoparticles can inhibit the growth and biofilm formation of Acinetobacter baumannii, a bacterium that causes severe hospital-acquired infections like pneumonia and bloodstream infections. Researchers will collect samples from 150 patients in Sohag University Hospitals, identify A. baumannii strains, and test their antibiotic resistance. In the lab, they will expose these bacteria to different concentrations of zinc oxide nanoparticles to see if the particles can disrupt biofilms and affect genes related to resistance and biofilm formation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zinc oxide nanoparticles (ZnO NPs) tested in the lab against A. baumannii bacteria
- What this could lead to
- If effective, ZnO NPs could become a new tool against drug-resistant A. baumannii infections, potentially reducing mortality in hospitals.
- What could go wrong
- This is a lab-based study, not a clinical treatment trial. Results may not translate to real-world use, and safety in humans is not yet tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS, NOSOCOMIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sohag university, Faculty of medicine
Sohag, 534568, Egypt